JXN

Jackson Financial Inc.

$127.12

-1.88%
Nov 20, 2026
Bobby Quantitative Model
Jackson Financial Inc. is a US retirement-services specialist that designs, distributes and manages annuities — variable, fixed index, registered index-linked (RILA) and fixed/payout products — through its Retail Annuities, Institutional Products and Closed Life & Annuity Blocks segments, with the retail annuity book generating the overwhelming majority of revenue. Spun off from Prudential plc in 2021, Jackson is a scaled, brand-recognized annuity manufacturer with a large in-force variable annuity block and a distribution network of independent advisors and wirehouses, positioning it as a capital-return-oriented, spread-and-fee-driven life insurer rather than a growth platform. The current investor debate centers on the durability of the Q3 2026 earnings surge — net income of $870 million and diluted EPS of $12.37 — which was heavily flattered by mark-to-market gains on hedged separate-account assets rather than core spread income, alongside a 3.6% dividend yield and an aggressive buyback program that have made the stock a momentum favorite (+47% over twelve months). With only one sell-side EPS estimate on file and a wide dispersion between GAAP and adjusted results, the narrative is split between bulls who see a cheap, cash-generative capital return story and skeptics who warn that equity-market-sensitive earnings and a shrinking share count mask limited underlying earnings power.

People also watch

MetLife

MetLife

MET

Analysis
Aflac

Aflac

AFL

Analysis
Prudential Financial

Prudential Financial

PRU

Analysis
Unum

Unum

UNM

Analysis
Globe Life

Globe Life

GL

Analysis

BobbyInvestment Opinion: Should I buy JXN Today?

Rating: Hold. Jackson is a cheap, cash-generative annuity manufacturer trading at 0.75x book with a 3.57% dividend yield and $5.932 billion of TTM free cash flow, but a near-zero trailing ROE of 0.27% and Q3 2026 net income of $870 million that was produced despite a $34 million operating loss mean the earnings base is not yet proven recurring. The only published analyst signal is Barclays' Overweight (reiterated 2026-11-04), balanced by Evercore ISI In Line and KBW Market Perform, and with a single $46.60 EPS estimate and no consensus price target, there is no reliable implied upside to anchor a more aggressive stance.

The supporting evidence is genuinely attractive on cash and valuation: 0.75x P/B versus a typical life-insurer range of roughly 1.0x-1.5x, a 1.12x PS and 1.30x P/CF, a forward PE of 4.36x on the $46.60 estimate, a payout ratio of just 9.9%, debt-to-equity of 0.46 and a current ratio of 4.52. Q3 2026 revenue of $1.542 billion grew 14.31% year-over-year and the company returned $233 million of buybacks plus $70 million of dividends while cash rose to $4.101 billion. But the profitability trend cuts the other way: TTM net margin is 0.40%, operating margin -1.71%, and quarterly EPS has swung from -$6.24 (Q1 2026) to $9.16 (Q2 2026) to $12.37 (Q3 2026), so the 4.36x forward multiple rests entirely on an estimate that has not been validated by reported results.

The biggest risks that could invalidate the thesis are an equity-market reversal that flips the $1.034 billion of hedging marks in Q3 into losses, a failure of adjusted operating earnings to approach the $46.60 estimate, and thin three-firm coverage that leaves price discovery inefficient. This Hold would upgrade to Buy if Jackson reports two consecutive quarters of positive operating income with ROE moving toward mid-single digits, or if the stock pulls back toward the $102-$110 zone while book value holds; it would downgrade to Sell if operating income stays negative for another quarter or if P/B pushes above 1.0x without book-value growth. Verdict: fairly valued to modestly undervalued on book and cash flow, but not undervalued on demonstrated earnings power — the 47.46% twelve-month rally has already captured much of the re-rating case.

Sign up to view all

JXN 12-Month Price Forecast

Jackson presents a genuine valuation-versus-earnings-quality standoff: at 0.75x book and 4.36x the single forward EPS estimate the stock looks deeply cheap, and $5.932 billion of TTM free cash flow plus a 9.9% payout ratio give the 3.57% dividend a solid floor. But the trailing record is poor — 0.27% ROE, 0.40% net margin, a -$34 million operating loss in the most recent quarter — and the $870 million Q3 profit was manufactured by $1.034 billion of mark-to-market gains rather than spread income, so the forward multiple rests on an unvalidated estimate. Momentum is strong (+47.46% over twelve months versus SPY's 12.27%) but the stock sits at roughly 96% of its 52-week range after re-rating from 0.40x book in Q4 2023, leaving little cushion if the marks reverse. I would upgrade to bullish on two consecutive quarters of positive operating income with ROE trending toward mid-single digits, or on a pullback toward the $102-$110 support zone with book value intact; I would downgrade to bearish if operating income stays negative or if P/B exceeds 1.0x without book-value growth.

Historical Price
Current Price $127.12
Average Target $127.12
High Target $146.19
Low Target $108.05

Wall Street consensus

Coverage is extremely thin: only one analyst has submitted an EPS estimate ($46.60, with identical low and high values) and average estimated revenue of $9.917 billion, so there is no meaningful consensus target price or Buy/Hold/Sell distribution to compute an implied upside from. The institutional ratings feed shows a small but consistent group — Barclays reiterating Overweight on 2026-11-04, 2026-10-08 and 2026-10-07, Evercore ISI maintaining In Line on 2026-10-07 and 2026-09-18, and Keefe, Bruyette & Woods at Market Perform on 2026-09-18 and 2026-08-05 — which collectively leans neutral-to-moderately-positive but reflects only three firms and no recent upgrades or downgrades. With no published price targets in the dataset, I cannot state a consensus target or implied upside; the signal from the ratings alone is a mild bullish tilt anchored by Barclays' Overweight.\n\nThe absence of a target range means we cannot assess what the high and low cases assume, but the single $46.60 EPS estimate is itself the key signal: it implies roughly $3.2 billion of net income on 68.3 million diluted shares, a dramatic swing from the current near-zero TTM EPS, and likely reflects adjusted operating earnings rather than GAAP. A wide or undefined target spread would normally signal high uncertainty, and here the uncertainty is structural — GAAP results swing by billions of dollars quarter to quarter on hedging marks, which makes sell-side modeling difficult and discourages coverage. Limited coverage of a $7.5-$9.3 billion market-cap insurer typically means less efficient price discovery and higher volatility around earnings, so investors should treat the Barclays Overweight as a single high-conviction data point rather than a broad consensus, and watch for additional initiations as a potential catalyst for re-rating.

Drowning in data?

Find the real signal!

Bulls vs Bears: JXN Investment Factors

The bear case currently has stronger evidence on the fundamentals: trailing ROE of 0.27%, an operating margin of -1.71%, and a Q3 profit that was entirely a function of $1.034 billion of hedging and investment marks rather than core spread income. The bull case rests on valuation and cash return — 0.75x book, $5.932 billion of TTM free cash flow, a 3.57% dividend with a 9.9% payout ratio, and a forward PE of 4.36x if the single analyst's $46.60 estimate is achievable. Momentum is unambiguously bullish (+47.46% over twelve months, 35.19 points of relative strength versus SPY), but the stock sits at roughly 96% of its 52-week range after a rally driven by re-rating rather than book-value growth. The single most important tension is whether Jackson can convert market-driven GAAP earnings into stable adjusted operating income — if the $46.60 forward EPS proves to be genuine recurring earnings power, the stock is dramatically undervalued at 4.36x; if GAAP results keep oscillating with equity markets and ROE stays near zero, 0.75x book is fair-to-full and the rally has borrowed from future returns.

Bullish

  • Deep discount to book value: JXN trades at 0.75x price-to-book versus a typical life-insurer range of roughly 1.0x-1.5x, a 25%-50% discount. Even after a 47.46% twelve-month rally, the stock is priced below the accounting value of its equity, and the PS of 1.12x and P/CF of 1.30x are low in absolute terms.
  • Massive cash generation funds returns: TTM free cash flow is $5.932 billion against a market cap of roughly $7.5-$9.3 billion, and Q3 2026 operating cash flow alone was $1.417 billion. That cash funded $233 million of buybacks and $70 million of dividends in the quarter while cash still grew to $4.101 billion.
  • Forward EPS implies extreme cheapness: The single analyst estimate of $46.60 in forward EPS produces a forward PE of just 4.36x, implying roughly $3.2 billion of net income on 68.3 million diluted shares. If even a fraction of that adjusted operating earnings materializes, the current $138.95 price is extraordinarily low relative to earnings power.
  • Persistent relative-strength leadership: JXN is up 47.46% over twelve months versus SPY's 12.27%, a 35.19-point relative-strength advantage, and 26.51% over six months versus 2.13% for SPY. The one-month gain of 6.86% against SPY's -2.26% shows momentum re-accelerating after the September pullback, with the stock at roughly 96% of its 52-week range.

Bearish

  • Earnings are hedging marks, not operations: Q3 2026 net income of $870 million (EPS $12.37) came alongside an operating loss of $34 million, because $1.034 billion of total other income — largely mark-to-market gains on hedged separate-account assets — drove the profit. Core spread income is not what produced the headline number, so the earnings surge is not repeatable on demand.
  • Near-zero trailing ROE and margins: TTM net margin is 0.40%, operating margin is -1.71%, ROE is 0.27% and EPS is essentially zero at $0.0036, reflecting the Q1 2026 loss of $424 million and Q4 2025 loss of $204 million. A near-zero ROE is well below the mid-single to low-double-digit range typical for life insurers, meaning book value is barely compounding.
  • Revenue is wildly volatile and distorted: Quarterly revenue swung from $2.902 billion in Q1 2026 to $168 million in Q2 2026 to $1.542 billion in Q3 2026, and Q2 2025 was a negative $483 million. The 14.31% YoY growth in Q3 is a noisy proxy because realized and unrealized investment gains flow through the top line, limiting any reliable growth extrapolation.
  • Valuation at the top of its own history: P/B has climbed from 0.40x in Q4 2023 and 0.60x-0.69x through 2025 to 0.75x today, the richest level since the 2021 spin-off. The re-rating reflects the 47% rally rather than book-value growth, so further upside now requires multiple expansion the fundamentals do not yet support.

JXN Technical Analysis

JXN is in a powerful, sustained uptrend: the stock is up 47.46% over the trailing year and 29.30% year-to-date, closing at $138.95 on 2026-11-13 versus a 180-day closing low of $102.39 (2026-06-30) and a high of $140.65 (2026-11-03). That places the current price at roughly 96% of its 52-week range — near the top of the band — which signals strong momentum but also meaningful overextension risk, particularly given the stock has already delivered a 35.19 percentage-point relative-strength advantage over SPY (+12.27%) over the same period. The 180-day maximum drawdown of -17.03% shows the stock does correct sharply when momentum breaks, so positioning near highs warrants disciplined stop management rather than indiscriminate chasing.\n\nShort-term momentum is re-accelerating after a brief pause: the stock gained 6.86% over the past month versus a -2.26% decline for SPY, a 9.12-point relative-strength spread, and is up 2.68% over three months against SPY's -2.83%. The one-month gain outpacing the three-month gain (6.86% vs. 2.68%) indicates the trend has reasserted itself after the September consolidation that saw the stock fall from $140.63 (2026-09-04) to $129.38 (2026-09-17), a roughly 8% pullback that was absorbed and reversed. The 26.51% six-month gain versus SPY's 2.13% confirms this is a persistent relative-strength leader rather than a one-off spike, though the absence of volume data in the feed limits confirmation of accumulation on the recent push toward $140.\n\nKey technical levels are well defined: resistance sits at the $140.65 52-week high, with a decisive breakout above that level opening the door to blue-sky territory and likely triggering momentum-fund inflows; support rests at the $129-$130 shelf established in September and October, with the more meaningful floor at the $102.39 June low. A breakdown below $129 would signal a failed breakout and put the 50-day trend in question, while a loss of $102 would invalidate the entire uptrend. Volatility is elevated — the -17.03% max drawdown and a 47% annual gain imply a beta well above 1.0 relative to the market, meaning position sizing should be scaled down accordingly; a 1.5x-style volatility profile would argue for roughly two-thirds the capital allocation of an equivalent S&P 500 position for the same risk budget.

Beta

—

—

Max Drawdown

-17.0%

Largest decline past year

52-Week Range

—

Price range past year

Annual Return

+38.4%

Cumulative gain past year

PeriodJXN ReturnS&P 500
1m-2.3%-9.7%
3m-2.1%-9.9%
6m+18.9%-7.5%
1y+38.4%+4.7%
ytd+18.3%+1.2%

Bobby - Your AI Investment Partner

Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions

JXN Fundamental Analysis

Revenue is highly volatile and distorted by GAAP accounting for annuity liabilities: Q3 2026 revenue was $1.542 billion, up 14.31% year-over-year from $1.349 billion in Q3 2025, but the quarterly series swings wildly — Q2 2026 showed $168 million, Q1 2026 $2.902 billion, Q4 2025 $2.094 billion and Q2 2025 a negative $483 million — because realized and unrealized investment gains/losses flow through the top line. Segment data for the latest period shows Retail Annuities at $1.626 billion, Closed Life & Annuity Blocks at $275 million and Institutional Products at $144 million, confirming that retail annuities are the growth engine and the institutional/closed blocks are runoff or opportunistic. The 14.31% YoY growth is encouraging on the surface, but investors should treat it as a noisy proxy — the underlying driver is annuity sales and spread income, not a clean recurring revenue base, which limits the reliability of any growth extrapolation.\n\nProfitability is similarly bifurcated between GAAP and economic reality: Q3 2026 net income was $870 million (a 56.4% net margin) on gross profit of $962 million (62.4% gross margin), yet operating income was a loss of $34 million (-2.2% operating margin) because the reported profit was driven by $1.034 billion of total other income — largely hedging and investment marks — rather than core operations. The trailing twelve-month picture is worse: net margin of just 0.40%, operating margin of -1.71%, ROE of 0.27% and EPS of essentially zero ($0.0036), reflecting the Q1 2026 loss of $424 million and Q4 2025 loss of $204 million. Margins are therefore not expanding on a sustainable basis — they are oscillating with equity markets and interest rates, and the 85.5% gross margin in the valuation data versus 62.4% in the quarterly filing underscores how inconsistent the accounting presentation is. For a life insurer, a mid-single-digit to low-double-digit ROE is typical; Jackson's near-zero TTM ROE is well below peer norms and signals that book-value growth is currently being consumed by hedging costs and market moves.\n\nThe balance sheet and cash generation are the strongest part of the story: free cash flow TTM is $5.932 billion, Q3 2026 operating cash flow was $1.417 billion, debt-to-equity is a modest 0.46, and the current ratio of 4.52 indicates ample liquidity. The company returned capital aggressively in Q3 — $233 million of buybacks and $70 million of dividends — while still growing cash to $4.101 billion, and the dividend yield of 3.57% is well covered by a payout ratio of just 9.9% on the forward EPS estimate. However, the $8.16 billion of investment purchases in Q3 versus $3.395 billion of maturities shows the insurer is actively repositioning its portfolio, and the negative $1.885 billion net change in cash for the quarter is a reminder that cash flow is reinvested into the annuity book rather than freely distributable. On balance, Jackson funds itself internally and does not depend on external financing, but the FCF figure overstates distributable earnings because much of it is statutory capital supporting reserves.

Quarterly Revenue

$1.5B

2026-09

Revenue YoY Growth

+14.3%

YoY Comparison

Gross Margin

62.4%

Latest Quarter

Free Cash Flow

$5.9B

Last 12 Months

Revenue & Net Income Trends (2 Years)

Revenue Breakdown

Closed Life And Annuity Blocks Segment
Institutional Products Segment
Retail Annuities Segment

Open an Account, get $2 TSLA now!

Valuation Analysis: Is JXN Overvalued?

Because trailing net income is effectively zero (EPS of $0.0036) and TTM EBITDA is negative, the trailing PE of -444.4x and EV/EBITDA of -455.6x are meaningless — I therefore lead with the price-to-book ratio of 0.75x and the forward PE of 4.36x, which are the only metrics that reflect the economics of a life insurer. The forward PE of 4.36x is derived from the single analyst EPS estimate of $46.60 for the coming year, implying the market expects a dramatic earnings normalization from the current near-zero base; the enormous gap between the -444x trailing and 4.36x forward multiple tells you the market is pricing a recovery that has not yet been delivered, and the PEG ratio of 4.36x suggests that even on forward numbers the growth-adjusted valuation is not cheap.\n\nAgainst the life-insurance industry, Jackson screens cheap on book value: a P/B of 0.75x versus a typical life-insurer range of roughly 1.0x-1.5x represents a 25%-50% discount, and the PS ratio of 1.12x and P/CF of 1.30x are also low in absolute terms. The discount is partly justified — a near-zero TTM ROE of 0.27%, negative operating margins and earnings dominated by hedging marks are inferior to peers with stable spread income — but the 3.57% dividend yield and $5.9 billion FCF provide a valuation floor that the market is not fully crediting. In short, the stock is cheap for a reason, and the re-rating case depends on converting market-driven GAAP earnings into stable adjusted operating income.\n\nOn its own history, the stock is at the high end of its valuation band: the P/B ratio has climbed from 0.40x in Q4 2023 and 0.60x-0.69x through 2025 to 0.75x today, and the historical PE series has swung from 0.28x-9.5x in profitable quarters to deeply negative readings in loss quarters. The current 0.75x book multiple is the richest since the 2021 spin-off era and reflects the 47% twelve-month rally rather than an improvement in book value per share — meaning the market is now pricing in optimistic expectations for capital return and earnings normalization. If forward EPS of $46.60 materializes, the stock is extraordinarily cheap at 4.36x; if GAAP earnings remain volatile and ROE stays near zero, the 0.75x book value is fair-to-full and further upside requires multiple expansion that the fundamentals do not yet support.

PE

-444.4x

Latest Quarter

vs. Historical

Low-End

5-Year PE Range 0x~9x

vs. Industry Avg

11.7x

Industry PE ~11.7x*

EV/EBITDA

-455.6x

Enterprise Value Multiple

Investment Risk Disclosure

Financial and operational risks are dominated by earnings quality rather than leverage. Q3 2026 net income of $870 million was produced despite an operating loss of $34 million, because $1.034 billion of other income — hedging and investment marks — carried the quarter, so a reversal in equity markets could swing results by billions: Q1 2026 already showed a $424 million loss and Q4 2025 a $204 million loss. TTM ROE of 0.27% and net margin of 0.40% mean book value is barely compounding, while the $5.932 billion TTM free cash flow overstates distributable earnings because much of it is statutory capital supporting annuity reserves. Revenue concentration compounds this: Retail Annuities generated $1.626 billion of the latest period's revenue versus $275 million from Closed Blocks and $144 million from Institutional Products, so the entire thesis hinges on a single product line whose results are equity-market sensitive. Debt-to-equity of 0.46 and a current ratio of 4.52 are comfortable, but the negative $1.885 billion net change in cash in Q3, with $8.16 billion of investment purchases against $3.395 billion of maturities, shows cash is continuously reinvested into the book rather than freely available. Market and competitive risks center on valuation compression. At 0.75x book — the richest since the 2021 spin-off, up from 0.40x in Q4 2023 — the stock has re-rated without book-value growth, and the PEG ratio of 4.36x signals that even on forward numbers the growth-adjusted valuation is not cheap. Coverage is a structural vulnerability: only one EPS estimate exists ($46.60, identical low and high) and just three firms publish ratings (Barclays Overweight, Evercore In Line, KBW Market Perform), so there is no consensus target to anchor price and limited coverage of a $7.5-$9.3 billion insurer means inefficient price discovery and higher volatility around earnings. The stock's 47% annual gain and -17.03% maximum drawdown imply a beta well above 1.0, and with the price at roughly 96% of its 52-week range after a 35.19-point relative-strength advantage over SPY, sector rotation or a momentum break would hit JXN harder than the market. The worst-case scenario is a sharp equity-market decline that reverses the hedging marks, turning Q3's $870 million profit into a loss while simultaneously pressuring fee income on the separate-account book and forcing reserve strengthening. In that chain, the stock would retest the $102.39 June 2026 low, a decline of roughly 26% from the current $138.95, and a deeper break toward the 0.60x book multiple seen through 2025 would imply further downside beyond that level. With no analyst low target published, the 52-week low is the best available downside anchor, and the -17.03% maximum drawdown over the past 180 days shows how quickly the stock corrects once momentum breaks — an investor should size positions assuming a realistic 25%-35% drawdown in an adverse scenario.

FAQ

The most severe risk is earnings quality: Q3 2026's $870 million profit was manufactured by $1.034 billion of hedging and investment marks while operations lost $34 million, and Q1 2026 already showed a $424 million loss, so an equity-market decline could swing results by billions and retest the $102.39 low. Second is valuation compression — at 0.75x book, the richest since the 2021 spin-off, further upside requires multiple expansion rather than book-value growth, and the -17.03% maximum drawdown over 180 days shows how fast the correction can come. Third is revenue concentration in Retail Annuities, which produced $1.626 billion of the latest period's revenue versus $275 million from Closed Blocks and $144 million from Institutional Products, leaving the thesis dependent on one equity-sensitive product line. Fourth is structural information risk: only one EPS estimate exists ($46.60, identical low and high) and just three firms publish ratings, so price discovery is inefficient and the stock is prone to sharp moves around earnings.

The base case, at 50% probability, targets $130-$150 and assumes P/B holds near 0.75x with Retail Annuities remaining the stable core, the 3.57% dividend maintained and no new analyst coverage emerging — essentially the stock holding near its $140.65 high without further multiple expansion. The bull case, at 25%, targets $160-$175 and requires adjusted operating earnings to track toward the $46.60 EPS estimate, re-rating the multiple toward 0.9x-1.0x book on continued buybacks and compounding book value per share. The bear case, at 25%, targets $95-$110 and assumes an equity selloff flips the hedging marks into losses, pushing results back toward the Q1 2026 loss and retesting the $102.39 low. The base case is most likely because it requires nothing to go right beyond the status quo, but the key assumption — that the single $46.60 estimate proves too optimistic on a GAAP basis while adjusted operating earnings stay positive enough to fund capital returns — is exactly what makes the 4.36x forward multiple unreliable as a valuation anchor.

The answer depends entirely on which earnings base you trust. On book value, JXN is cheap: 0.75x P/B against a typical life-insurer range of 1.0x-1.5x is a 25%-50% discount, and the 1.12x PS and 1.30x P/CF are low in absolute terms. On forward earnings it looks extraordinarily cheap at 4.36x the single $46.60 EPS estimate, but that estimate implies roughly $3.2 billion of net income versus a current TTM EPS of essentially zero, so the market is clearly not crediting it — the -444x trailing PE and -455.6x EV/EBITDA are artifacts of near-zero and negative earnings. Against its own history the stock is at the top of its band, with P/B up from 0.40x in Q4 2023 and 0.60x-0.69x through 2025 to 0.75x today, the richest since the 2021 spin-off. The market is therefore paying a fair-to-full price on book for a business whose earnings quality is unproven, and the PEG ratio of 4.36x confirms the growth-adjusted valuation is not cheap even on optimistic forward numbers.

The risk/reward is balanced rather than compelling at $138.95. On the positive side, JXN trades at 0.75x book versus a typical life-insurer range of roughly 1.0x-1.5x, carries a 3.57% dividend at just a 9.9% payout ratio, and generates $5.932 billion of TTM free cash flow against a $7.47 billion market cap, while the single forward EPS estimate of $46.60 implies a 4.36x forward PE. On the negative side, trailing ROE is 0.27%, operating margin is -1.71%, and Q3 2026's $870 million profit came despite a $34 million operating loss because $1.034 billion of hedging and investment marks carried the quarter. The biggest downside risk is a momentum unwind back to the $102.39 June 2026 low, roughly 26% below the current price, and with only three firms covering and no consensus target, there is no analyst upside figure to anchor the case. It is a reasonable buy for income-oriented value investors who can tolerate GAAP volatility and size for a 25%-35% drawdown, and a poor buy for anyone buying the 47.46% twelve-month rally for momentum.

JXN is better suited to a long-term holding period of at least two to three years than to short-term trading, because the thesis depends on converting market-driven GAAP earnings into stable adjusted operating income — a multi-quarter process, not a single catalyst. The stock's volatility profile argues against short-term entry at current levels: it is up 47.46% over twelve months versus SPY's 12.27%, sits at roughly 96% of its 52-week range, and has shown a -17.03% maximum drawdown in just 180 days, implying a beta well above 1.0. The 3.57% dividend, covered by a 9.9% payout ratio, rewards patience and provides a floor, while the $233 million quarterly buyback shrinks the 68.3 million diluted share count and compounds book value per share over time. A reasonable approach is a staged position with a minimum two-year horizon, adding on pullbacks toward the $102-$110 support zone where book value remains intact, rather than chasing the momentum near $140.